A Study to Evaluate the Clinical Significance of Circulating CD33, CD11b, HLA-DR- MDSCS as Prognostic and Predictive Biomarkers of Response and Overall-Survival in Stage IV Melanoma Patients Treated With Ipilimumab

Trial Profile

A Study to Evaluate the Clinical Significance of Circulating CD33, CD11b, HLA-DR- MDSCS as Prognostic and Predictive Biomarkers of Response and Overall-Survival in Stage IV Melanoma Patients Treated With Ipilimumab

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 20 May 2016 New trial record
    • 13 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top